GlassScriptPhysician profile
Sara T Partida
NPI 1285160622
$12,141.93
in general payments reported to CMS, 2019-2025
25 companies · $2,254 in 2025
The $2,254 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,247 · 2022: $1,797 · 2023: $2,915 · 2024: $3,927 · 2025: $2,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,744 · Travel and Lodging: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,743.53 |
| Travel and Lodging | $353.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,151.35 | 2021-2025 | |
| Boston Scientific Corporation | $1,958.05 | 2022-2025 | Watchman Access System, Watchman, Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $1,056.45 | 2021-2025 | Farxiga, Lokelma |
| Janssen Pharmaceuticals, INC | $1,021.79 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $918.18 | 2022-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $740.71 | 2021-2025 | Eliquis, Camzyos |
| Amgen INC. | $623.36 | 2021-2025 | Repatha, Repatha |
| Abbott Laboratories | $580.89 | 2021-2025 | Cardiomems, Jot Dx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $558.53 | 2021-2025 | Lifevest |
| Pfizer INC. | $461.60 | 2021-2025 | |
| Novo Nordisk INC | $346.08 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $338.23 | 2022-2025 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $296.42 | 2024 | Inpefa |
| Scpharmaceuticals INC. | $211.50 | 2024-2025 | |
| Cvrx, INC. | $165.99 | 2025 | Barostim Neo System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $154.06 | 2024-2025 | Nexletol |
| Kestra Medical Technology Services, INC. | $126.65 | 2023-2025 | Assure Wcd |
| Heartflow, INC. | $117.27 | 2024-2025 | |
| Impulse Dynamics (USA) INC. | $111.26 | 2024 | Optimizer |
| Alnylam Pharmaceuticals INC. | $74.32 | 2025 | Amvuttra |
| Edwards Lifesciences Corporation | $52.76 | 2023-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lilly USA, LLC | $22.15 | 2025 | Zepbound, Mounjaro |
| Actelion Pharmaceuticals US, INC. | $20.60 | 2024 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $17.02 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Partida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.